Cargando…

Predicting treatment response to IL6R blockers in rheumatoid arthritis

Patients with severe, active RA who have not responded to conventional therapy may receive biological disease modifying anti-rheumatic drugs (bDMARDs). However, 40% of cases do not achieve complete disease control, resulting in a negative impact on patient quality of life and representing a waste of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nouri, Bako, Nair, Nisha, Barton, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733712/ https://www.ncbi.nlm.nih.gov/pubmed/32864695 http://dx.doi.org/10.1093/rheumatology/keaa529

Ejemplares similares

Genetics of rheumatoid arthritis susceptibility, severity, and treatment response
por: Viatte, Sebastien, et al.
Publicado: (2017)

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
por: Maciejewski, Mateusz, et al.
Publicado: (2021)

Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis
por: Sainz, Luis, et al.
Publicado: (2022)

Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis
por: Mulhearn, Ben, et al.
Publicado: (2019)

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response
por: Cherlin, Svetlana, et al.
Publicado: (2020)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
por: Sainz, Luis, et al.
Publicado: (2023)

T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy
por: Dulic, Sonja, et al.
Publicado: (2017)

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients
por: Ling, Stephanie F., et al.
Publicado: (2019)

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis
por: Nair, Nisha, et al.
Publicado: (2020)

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis
por: Wang, Jianmei, et al.
Publicado: (2013)

Methylation Pattern of the SOCS3 and IL6R Promoters in Rheumatoid Arthritis
por: Cieśla, Marek, et al.
Publicado: (2020)

Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis
por: Blair, J. P. M., et al.
Publicado: (2020)

The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment
por: Kalogera, Stefania, et al.
Publicado: (2021)

Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
por: Yoshizaki, K, et al.
Publicado: (2003)

On the Role of sIL-2R Measurements in Rheumatoid Arthritis and Cancers
por: Witkowska, Anna Maria
Publicado: (2005)

Clinical Value of IL6R Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis
por: Sainz, Luis, et al.
Publicado: (2022)

Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2016)

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis
por: Favalli, Ennio G.
Publicado: (2020)

Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
por: Hennigan, Stephanie, et al.
Publicado: (2008)

Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2019)

Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
por: Barton, Jennifer L
Publicado: (2009)

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score
por: Gilani, Syed SA, et al.
Publicado: (2020)

Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: OIiver, James, et al.
Publicado: (2021)

Interleukin-6 in Rheumatoid Arthritis
por: Pandolfi, Franco, et al.
Publicado: (2020)

Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study
por: Kumar, Kanta, et al.
Publicado: (2016)

Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: Oliver, James, et al.
Publicado: (2021)

Determination of Heterogeneous Proteomic and Metabolomic Response in anti-TNF and anti-IL-6 Treatment of Patients with Rheumatoid Arthritis
por: Stepanov, Alexander A., et al.
Publicado: (2023)

Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis
por: Li, Songsong, et al.
Publicado: (2016)

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
por: Smith, Samantha Louise, et al.
Publicado: (2023)

-Omic Approaches and Treatment Response in Rheumatoid Arthritis
por: Madrid-Paredes, Adela, et al.
Publicado: (2022)

Interleukin 6 and Rheumatoid Arthritis
por: Yoshida, Yuji, et al.
Publicado: (2014)

Prediction of treatment response in rheumatoid arthritis patients using genome‐wide SNP data
por: Cherlin, Svetlana, et al.
Publicado: (2018)

Types of pain and their psychosocial impact in women with rheumatoid arthritis
por: Chancay, Maria Gabriela, et al.
Publicado: (2019)

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
por: Sellam, Jérémie, et al.
Publicado: (2016)

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNFα Blocker Treatment
por: Khanniche, Asma, et al.
Publicado: (2019)

Disease Activity Is More Associated with IL-1 Than with IL-6 in Patients with Rheumatoid Arthritis
por: Almeida-Santiago, Cristina, et al.
Publicado: (2022)

Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis
por: Burgos, Paula I, et al.
Publicado: (2010)

Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritis
por: Kawashima, Masanori, et al.
Publicado: (2004)

Investigation of association of the IL12B and IL23R genes with psoriatic arthritis
por: Filer, Charlotte, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ckp4b55e1n02j8ufh2p6v8vj1h